{"title":"复发难治性多发性骨髓瘤患者心肌淀粉样变性的成功控制：1例报告及文献复习。","authors":"Yayoi Ueda, Toshiki Terao, Nobuharu Fujii, Tatsuji Mino, Saya Kubota, Kenta Hayashino, Kanako Fujiwara, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Hideo Tanaka, Yoshinobu Maeda","doi":"10.1007/s12185-025-04016-x","DOIUrl":null,"url":null,"abstract":"<p><p>A 50-year-old Japanese man with penta-drug refractory multiple myeloma (MM) was found to have stage IIIa cardiac immunoglobulin light-chain amyloidosis before idecabtagene vicleucel (ide-cel) therapy. Ide-cel therapy was started after careful consideration and hospital ethics committee approval. Grade 3 cytokine release syndrome and atrial flutter occurred in the acute phase after ide-cel infusion, but these were well-tolerated with supportive care in the intensive care unit. The patient achieved stringent complete response at day 60 and cardiac response at 9 months after ide-cel infusion with the addition of catheter ablation for sustained atrial flutter on day 133. He has maintained both hematological and cardiac remission for over 1 year since ide-cel therapy. This case highlights the effectiveness of ide-cel for disease control in heavily pretreated MM with cardiac amyloidosis.</p>","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"616-622"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.\",\"authors\":\"Yayoi Ueda, Toshiki Terao, Nobuharu Fujii, Tatsuji Mino, Saya Kubota, Kenta Hayashino, Kanako Fujiwara, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Hideo Tanaka, Yoshinobu Maeda\",\"doi\":\"10.1007/s12185-025-04016-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A 50-year-old Japanese man with penta-drug refractory multiple myeloma (MM) was found to have stage IIIa cardiac immunoglobulin light-chain amyloidosis before idecabtagene vicleucel (ide-cel) therapy. Ide-cel therapy was started after careful consideration and hospital ethics committee approval. Grade 3 cytokine release syndrome and atrial flutter occurred in the acute phase after ide-cel infusion, but these were well-tolerated with supportive care in the intensive care unit. The patient achieved stringent complete response at day 60 and cardiac response at 9 months after ide-cel infusion with the addition of catheter ablation for sustained atrial flutter on day 133. He has maintained both hematological and cardiac remission for over 1 year since ide-cel therapy. This case highlights the effectiveness of ide-cel for disease control in heavily pretreated MM with cardiac amyloidosis.</p>\",\"PeriodicalId\":13992,\"journal\":{\"name\":\"International Journal of Hematology\",\"volume\":\" \",\"pages\":\"616-622\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12185-025-04016-x\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12185-025-04016-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.
A 50-year-old Japanese man with penta-drug refractory multiple myeloma (MM) was found to have stage IIIa cardiac immunoglobulin light-chain amyloidosis before idecabtagene vicleucel (ide-cel) therapy. Ide-cel therapy was started after careful consideration and hospital ethics committee approval. Grade 3 cytokine release syndrome and atrial flutter occurred in the acute phase after ide-cel infusion, but these were well-tolerated with supportive care in the intensive care unit. The patient achieved stringent complete response at day 60 and cardiac response at 9 months after ide-cel infusion with the addition of catheter ablation for sustained atrial flutter on day 133. He has maintained both hematological and cardiac remission for over 1 year since ide-cel therapy. This case highlights the effectiveness of ide-cel for disease control in heavily pretreated MM with cardiac amyloidosis.
期刊介绍：
The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
